title: The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents.
abstract: Development of alcohol use disorders largely depends on the effects of alcohol on the brain reward systems. Emerging evidence indicate that common mechanisms regulate food and alcohol intake and raise the possibility that endocrine signals from the gut may play an important role for alcohol consumption, alcohol-induced reward and the motivation to consume alcohol. Glucagon-like peptide 1 (GLP-1), a gastrointestinal peptide regulating food intake and glucose homeostasis, has recently been shown to target central brain areas involved in reward and motivation, including the ventral tegmental area and nucleus accumbens. Herein we investigated the effects of the GLP-1 receptor agonist, Exendin-4 (Ex4), on various measures of alcohol-induced reward as well as on alcohol intake and alcohol seeking behavior in rodents. Treatment with Ex4, at a dose with no effect per se, attenuated alcohol-induced locomotor stimulation and accumbal dopamine release in mice. Furthermore, conditioned place preference for alcohol was abolished by both acute and chronic treatment with Ex4 in mice. Finally we found that Ex4 treatment decreased alcohol intake, using the intermittent access 20% alcohol two-bottle-choice model, as well as alcohol seeking behavior, using the progressive ratio test in the operant self-administration model, in rats. These novel findings indicate that GLP-1 signaling attenuates the reinforcing properties of alcohol implying that the physiological role of GLP-1 extends beyond glucose homeostasis and food intake regulation. Collectively these findings implicate that the GLP-1 receptor may be a potential target for the development of novel treatment strategies for alcohol use disorders.
authors.affiliation: Institute of Neuroscience and Physiology, Department of Pharmacology, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
authors.forename: Emil
authors.initials: E
authors.lastname: Egecioglu
authors.forename: Pia
authors.initials: P
authors.lastname: Steensland
authors.forename: Ida
authors.initials: I
authors.lastname: Fredriksson
authors.forename: Kristin
authors.initials: K
authors.lastname: Feltmann
authors.forename: Jörgen A
authors.initials: JA
authors.lastname: Engel
authors.forename: Elisabet
authors.initials: E
authors.lastname: Jerlhag
mesh_terms: D000818:Animals; D002755:Choice Behavior / Q000187:drug effects*; D003216:Conditioning, Operant / Q000187:drug effects; D003213:Conditioning, Psychological / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D058999:Drug-Seeking Behavior / Q000187:drug effects* / Q000502:physiology*; D000431:Ethanol / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000502:physiology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology*; D051381:Rats; D012201:Reward; D012646:Self Administration; D014688:Venoms / Q000494:pharmacology*
chemical_list: D010455:Peptides; D014688:Venoms; D000431:Ethanol; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; D004298:Dopamine